We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Hologic Unveils Groundbreaking AI Research for Breast Cancer Detection

By MedImaging International staff writers
Posted on 01 Mar 2024

Hologic, Inc. (Marlborough, MA, USA) continues to deliver on its commitment to advancing women’s health by unveiling new research in artificial intelligence (AI) and offering innovative educational opportunities at the annual European Congress of Radiology (ECR) in Vienna, Austria from February 28 to March 2.

The pioneer behind 3D mammography, Hologic is presenting new data that showcase how next-generation deep-learning solutions can assist with breast cancer detection and improve workflow for radiologists. The research shows that Hologic’s Genius AI Detection solution has an exceptional ability to correctly match pairs of Regions of Interest (ROIs) in different views. In addition, Hologic is also presenting research highlighting how the Genius AI Detection algorithm can help radiologists identify potential cancers on mammograms previously interpreted as normal.


Image: The Genius AI Detection technology is commercially available in the U.S., with plans for rollout in Europe, Canada and Asia by the end of 2024 (Photo courtesy of Hologic)
Image: The Genius AI Detection technology is commercially available in the U.S., with plans for rollout in Europe, Canada and Asia by the end of 2024 (Photo courtesy of Hologic)

In a third study, Hologic is presenting research that demonstrates its deep learning-based AI algorithm can help significantly enhance performance, surpassing traditional machine learning Computer-Aided Detection (CAD) algorithms in specificity and overall effectiveness. In addition, Hologic and Bayer will be co-sponsoring a contrast-enhanced mammography (CEM) symposium, facilitated by globally recognized breast imaging radiologists. The symposium is designed to provide radiologists with an understanding of how CEM can be effectively implemented into their daily practice.

“These data reveal how AI can help us correlate ROIs in a way that we have never seen before, which underscores that deep-learning technology can supplement our workflow as radiologists and help us provide better patient care,” said esteemed breast imaging specialist and study author Dr. Sarah M. Friedewald, Associate Professor of Radiology and Chief of Breast Imaging at Northwestern Memorial Hospital. “Beyond its impact on our daily practices, these data emphasize the transformative potential AI has to drive improvements across the breast health spectrum. I’m looking forward to sharing this information with my colleagues from around the globe at ECR.”

“Research and education are central tenets of Hologic’s innovation, to support radiologists in achieving better patient outcomes,” added Tanja Brycker, Vice President, Strategic Development, Breast & Skeletal Health and Gynecological Surgical Solutions at Hologic. “We’re excited to present groundbreaking research at ECR and to continue our collaboration with Bayer on contrast-enhanced mammography. By offering our customers the opportunity to engage with world-renowned experts and explore our latest technology, we are ensuring they feel confident in their patient care procedures and decisions.”

Related Links:
Hologic, Inc. 


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
1.5T MRI System
uMR 670
New
Fetal Monitor
Avante Compact II
New
X-Ray QA Meter
Piranha CT

Latest ECR 2024 News

Vieworks Unveils Cutting-Edge X-ray Imaging Solutions

GE HealthCare Launches Elevated LOGIQ Ultrasound System Portfolio

Mindray Presents Future of Radiology at ECR 2024